- You will investigate commercial requirements - with therapeutic needs and market opportunities discussed
- You will see discussions of personalised medicine and biosimilar drugs in cancer treatment
- You will view expert opinion from our survey, including a full interview transcript.
That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends - predictions found only in our work. Our independent analysis helps you stay ahead in market knowledge.
You can order our report, receiving the market information you need
Our report can benefit everybody interested in cancer drug development, production, marketing and sales. We give predictions and answers you need. Please order our report now, making sure you don't miss out.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs
Table of Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research Methods
1.4 Scope of this Report
1.4.1 Drug Types Excluded from this Report
1.5 Abbreviations Used in this Report
2. Introduction: Cancer, its Physiology, Burden and Treatment
2.1 The Physiology of Cancer
2.1.1 Uncontrolled Growth
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer
18.104.22.168 The Developed World
22.214.171.124 The Developing World
2.3 Treating Tumours
2.3.2 Traditional Antineoplastics
2.3.3 Novel Antineoplastics
126.96.36.199 Kinase Receptor Antagonists
188.8.131.52 Other Nove
Copyright©2010 PR Newswire.
All rights reserved